Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 23:15:1343587.
doi: 10.3389/fphar.2024.1343587. eCollection 2024.

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration

Evgenia Koureta  1 , Evangelos Cholongitas  1
Affiliations
Review

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration

Evgenia Koureta et al. Front Pharmacol. .

Abstract

Non alcoholic fatty disease (NAFLD) is the most common chronic liver disease that is managed in the liver departments. It seems that the prevalence of the disease is rising worldwide and as it has the same pathogenetic pathways with metabolic syndrome, treatments that target components of the metabolic syndrome seem promising for the therapy of NAFLD as well. In this review we discuss the evolving role of semaglutide, which is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has been already approved for the treatment of type II diabetes mellitus (T2DM) and obesity.

Keywords: NAFLD; NASH; semaglutide combination; semaglutide orally; weekly semaglutide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Alkhouri N., Herring R., Kabler H., Kayali Z., Hassanein T., Kohli A., et al. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open label phase II trial. J. Hepatol. 77, 607–618. 10.1016/j.jhep.2022.04.003 - DOI - PubMed
    1. Arai T., Atsukawa M., Tsubota A., Ono H., Kawano T., Yoshida Y., et al. (2022). Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study. JGH Open 6 (7), 503–511. 10.1002/jgh3.12780 - DOI - PMC - PubMed
    1. Bækdal T. A., Thomsen M., Kupcova V., Hansen C. W., Anderson T. W. (2018). Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J. Clin. Pharmacol. 58 (10), 1314–1323. 10.1002/jcph.1131 - DOI - PMC - PubMed
    1. Blundell J., Finlayson G., Axelsen M. B., Flint A., Gibbons C., Kvist T., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes. Metab. 19, 1242–1251. 10.1111/dom.12932 - DOI - PMC - PubMed
    1. Brierley D. I., Holt M. K., Singh A., de Araujo A., McDougle M., Vergara M., et al. (2021). Central and peripheral GLP-1 systems independently suppress eating. Trapp. S. Nat. Metab. 3 (2), 258–273. 10.1038/s42255-021-00344-4 - DOI - PMC - PubMed

LinkOut - more resources